相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antidepressants and the risk of traumatic brain injury in the elderly: differences between individual agents
Federica Edith Pisa et al.
CLINICAL EPIDEMIOLOGY (2019)
Antidepressants and the Risk of Hemorrhagic Stroke in the Elderly: a Nested Case-Control Study
Wiebke Schaefer et al.
DRUG SAFETY (2019)
Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia
Kristine Macartney et al.
JAMA PEDIATRICS (2017)
The impact of the lookback period and definition of confirmatory events on the identification of incident cancer cases in administrative data
Jonas Czwikla et al.
BMC MEDICAL RESEARCH METHODOLOGY (2017)
The Risk of Ischemic Cardio- and Cerebrovascular Events Associated with Oxycodone-Naloxone and Other Extended-Release High-Potency Opioids: A Nested Case-Control Study
Kathrin Jobski et al.
DRUG SAFETY (2017)
Validating mortality in the German Pharmacoepidemiological Research Database (GePaRD) against a mortality registry
Christoph Ohlmeier et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2016)
Mortality in the German Pharmacoepidemiological Research Database (GePaRD) compared to national data in Germany: results from a validation study
Christoph Ohlmeier et al.
BMC PUBLIC HEALTH (2015)
Febrile seizures following measles and varicella vaccines in young children in Australia
Kristine K. Macartney et al.
VACCINE (2015)
Use of rivaroxaban in Germany: a database drug utilization study of a drug started in hospital
Kathrin Jobski et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Estimation of Background Incidence Rates of Guillain-Barre Syndrome in Germany - A Retrospective Cohort Study with Electronic Healthcare Data
Sabrina Hense et al.
NEUROEPIDEMIOLOGY (2014)
Analysis of safety data in children after receiving two doses of ProQuad® (MMRV)
Stephanie O. Klopfer et al.
VACCINE (2014)
Decline of varicella vaccination in German surveillance regions after recommendation of separate first-dose vaccination for varicella and measles-mumps-rubella
Andrea Streng et al.
VACCINE (2014)
Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination
Tania Schink et al.
VACCINE (2014)
Antidepressant drug use and off-label prescribing in children and adolescents in Germany: results from a large population-based cohort study
Michael Doerks et al.
EUROPEAN CHILD & ADOLESCENT PSYCHIATRY (2013)
Varicella vaccines
Andrew Flatt et al.
BRITISH MEDICAL BULLETIN (2012)
Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine Manufactured With Recombinant Human Albumin
Gabriela Rueger et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2012)
Measles-Containing Vaccines and Febrile Seizures in Children Age 4 to 6 Years
Nicola P. Klein et al.
PEDIATRICS (2012)
Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad®) in infants from 9 months of age
Limo Vesikari et al.
VACCINE (2012)
Measles-Mumps-Rubella-Varicella Combination Vaccine and the Risk of Febrile Seizures
Nicola P. Klein et al.
PEDIATRICS (2010)
Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age
Scott A. Halperin et al.
VACCINE (2009)
Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting
Steven J. Jacobsen et al.
VACCINE (2009)
A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra™): Immunogenicity and safety profile
Czajka Hanna et al.
VACCINE (2009)
Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine
Y. Gillet et al.
VACCINE (2009)
Establishment of a pharmacoepidemiological database in Germany: Methodological potential, scientific value and practical limitations
Iris Pigeot et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2008)
Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age
P. Goh et al.
INFECTION (2007)
Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years
Timo Vesikari et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2007)
分享论文
